General
Preferred name
L-tartaric acid
Synonyms
(2R,3R)-2,3-Dihydroxysuccinic acid ()
(2R,3R)-(+)-Tartaric acid ()
L(+)-Tartaric acid ()
tartaric acid ()
DL-Tartaric acid ()
TARTRATE ()
L-(+)-Tartaric acid ()
2,3-Dihydroxysuccinic acid ()
Threaric acid ()
Racemic acid ()
Uvic acid ()
Paratartaric acid ()
Winestone ()
E 334 ()
FEMA NO. 3044 ()
E-334 ()
NSC-62778 ()
INS-334 ()
Tartaric Acid ()
INS NO.334 ()
P&D ID
PD073856
CAS
87-69-4
1336-18-1
133-37-9
Tags
natural product
drug
available
Approved by
FDA
First approval
1985
Drug Status
experimental
investigational
approved
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Routes of Entry: Inhalation. Ingestion.; ; Toxicity to Animals:; Lowest Published Lethal Dose:; LDL [Rat - Route: oral; Dose: 7500 mg/kg; LDL [Rabbit] - Route: Oral; Dose: 5000 mg/kg; LDL [Dog] - Rout: Oral; Dose: 5000 mg/kg; Lethal Dose/Conc 50% kill:; LD50 [Mouse] - Route: Intravenous; Dose: 485 mg/kg; ; Other Toxic Effects on Humans:; Acute Potential Health Effects:; Skin: Causes skin irritation; Eyes: Causes eye irritation; Inhalation: Causes respiratory tract irritation; Ingestion: Causes gastrointestinal tract irritation with nausea, vomiting and diarrhea. May affect kidneys (kidney; damage), blood, and behavior (convulsions, somnolence), and respiration.; Chronic Potential Health Effects:; Ingestion: Repeated or prolonged ingestion may cause lesions of the mouth, gastric ulcers, gastrointestinal; hyperacidity, and symptoms similar to those of metal fume fever - flu-like condition with fever, chills, sweats,; nausea, vomiting, muscle aches, pains, and weakness.; Skin: Repeated or prolonged skin contact may cause skin ulcerations or lesions.;
PHARMACODYNAMICS
Tartaric acid is used to generate carbon dioxide through interaction with sodium bicarbonate following oral administration. Carbon dioxide extends the stomach and provides a negative contrast medium during double contrast radiography. In high doses, this agent acts as a muscle toxin by inhibiting the production of malic acid, which could cause paralysis and maybe death.;
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
40
Molecular Weight
150.02
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
3
Ring Count
0
Aromatic Ring Count
0
cLogP
-2.12
TPSA
115.06
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
0.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
oxidation-reduction
Metabolic Enzyme/Protease
Target
antioxidant
Endogenous Metabolite
MOA
Antioxidant
Source data
